Johnson & Johnson (JNJ)vsTriSalus Life Sciences Inc. (TLSI)
JNJ
Johnson & Johnson
$232.77
-0.20%
HEALTHCARE · Cap: $567.28B
TLSI
TriSalus Life Sciences Inc.
$3.30
+3.77%
HEALTHCARE · Cap: $223.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 214596% more annual revenue ($96.36B vs $44.88M). JNJ leads profitability with a 21.8% profit margin vs -60.9%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
TLSI
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.2%
Fair Value
$135.80
Current Price
$232.77
$96.97 premium
Intrinsic value data unavailable for TLSI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Trading at 15.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : TLSI
TLSI has a balanced fundamental profile.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : TLSI
The primary concerns for TLSI are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.69 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TLSI is a turnaround play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.49 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 16/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company focused on revolutionizing cancer treatment through its proprietary localized drug delivery systems. By enhancing the effectiveness of immuno-oncology agents and overcoming distribution challenges within tumor microenvironments, TriSalus is dedicated to improving therapeutic outcomes for cancer patients. With a promising pipeline of clinical programs, the company aims to meet the urgent demand for advanced cancer therapies. Positioned strategically within the dynamic oncology landscape, TriSalus is poised for significant impact as it seeks to expand access to its groundbreaking treatments.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?